header
Image from OpenLibrary

Detection of CD96 in acute myeloid leukemia patients and its relationship to remission induction chemotherapy / Heba Emad Abdelrahman Fahmy ; Supervised Sahar Kamal Eldin Hussein , Noha Mohamed Elhusseiny , Mohamed Ahmed Fateen

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Heba Emad Abdelrahman Fahmy , 2018Description: 140 P. : charts , facsimiles ; 25cmOther title:
  • الكشف عن سي دي 96 في مرضى سرطان الدم الميلودي الحاد وعلاقته بنتيجة العلاج الكيميائي [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology Summary: Background: Acute myeloid leukemia (AML) remains one of the most difficult malignancies to treat. Despite significant advancements in the understanding of disease biology, yet the relapse of AML remains frequent. Leukemic stem cells (LSCs) play a crucial role in chemotherapy resistance in AML, the classical LSCs phenotype is CD34+/CD38-.Successful eradication of LSCs require combination of different strategies including targeting LSC specific surface molecules. Aim of work: This study aimed for detection of CD96 in newly diagnosed AML as a leukemic stem cell marker and investigating the potential co-association between leukemic stem marker CD96 in de-novo acute myeloid leukemia patients and the response to induction therapy at day 28, to increase the understanding of the role of CD96 in AML diagnosis and prognosis. Patients and Methods: The current study was conducted on 50 patients with de-novo AML, in addition to 20 controls. Patients were selected among groups referred to clinical Hematology and medical oncology departments at Kasr Al- Aini hospital. Using multicolor flowcytometry, we analyzed the expression of CD96 among CD34+/CD38- cell population in AML patients at initial diagnosis and correlate it to the response of induction therapy
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.07.M.Sc.2018.He.D (Browse shelf(Opens below)) Not for loan 01010110076310000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.07.M.Sc.2018.He.D (Browse shelf(Opens below)) 76310.CD Not for loan 01020110076310000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology

Background: Acute myeloid leukemia (AML) remains one of the most difficult malignancies to treat. Despite significant advancements in the understanding of disease biology, yet the relapse of AML remains frequent. Leukemic stem cells (LSCs) play a crucial role in chemotherapy resistance in AML, the classical LSCs phenotype is CD34+/CD38-.Successful eradication of LSCs require combination of different strategies including targeting LSC specific surface molecules. Aim of work: This study aimed for detection of CD96 in newly diagnosed AML as a leukemic stem cell marker and investigating the potential co-association between leukemic stem marker CD96 in de-novo acute myeloid leukemia patients and the response to induction therapy at day 28, to increase the understanding of the role of CD96 in AML diagnosis and prognosis. Patients and Methods: The current study was conducted on 50 patients with de-novo AML, in addition to 20 controls. Patients were selected among groups referred to clinical Hematology and medical oncology departments at Kasr Al- Aini hospital. Using multicolor flowcytometry, we analyzed the expression of CD96 among CD34+/CD38- cell population in AML patients at initial diagnosis and correlate it to the response of induction therapy

Issued also as CD

There are no comments on this title.

to post a comment.